Elena V. Matvienko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elena V. Matvienko has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Tatyana Alekseevna Kryuchkova
Belgorod State National Research University
3 shared publications - Elena E. Balakireva
Belgorod State National Research University
2 shared publications A. O. Rumyantseva
Belgorod State National Research University
1 shared publication- Aleksej I. Ivanov
Belgorod State National Research University
1 shared publication - Arina A. Zherdeva
Belgorod State National Research University
1 shared publication E.D. Falalеeva
Children's Regional Clinical Hospital, Belgorod, Russia
1 shared publication
Latest Publications
- 20 May 2026
- Published by Open Systems Publications in Лечащий врач
- No. 5(29)
Progressive Duchenne/Becker muscular dystrophy, preclinical stage, deletion of exons 45-55 of the DMD gene in the hemizygous state: a clinical case from practice
Background. Duchenne/Becker progressive muscular dystrophy is an X-linked recessive disease caused by mutations in the DMD gene encoding the dystrophin protein. Deletions of exons 45-55 often correspond to the principle of preserving the reading frame, being associated with the Duchenne/Becker muscular dystrophy phenotype. Objective. To present a clinical case of the presymptomatic diagnosis of progressive Duchenne/Becker muscular dystrophy in an early-age patient with deletion of exons 45-55 of the DMD gene, analyze diagnostic markers and justify a strategy for dynamic follow-up. Materials and methods. A retrospective analysis of medical documentation with clinical, laboratory and instrumental methods was performed. In order to form a theoretical base, data was searched and systematized from scientific electronic libraries (CyberLeninka, eLibrary, PubMed, Google Academy) on progressive Duchenne/Becker muscular dystrophy (preclinical phase) and deletion of exons 45-55 of the DMD gene. The review includes literature reviews, scientific publications, and the results of clinical trials on the topic. Conclusion. A clinical case of diagnosis of progressive Duchenne/Becker muscular dystrophy in a 1-year-old male patient with isolated hyperfermentemia (ALT – 120 U/l, AST – 107.1 U/L) and a significant increase in creatine phosphokinase (4817.1 U/L) is described. Conducted: biochemical examination (creatine phosphokinase, lactate dehydrogenase, creatine phosphokinase-MV), instrumental diagnostics, including electrocardiography, ultrasound examination of the heart and abdominal cavity), molecular genetic analysis. The molecular genetic analysis method verified the hemizygous deletion of exons 45-55 of the DMD gene. The diagnosis of progressive Duchenne/Becker muscular dystrophy was established at the preclinical stage, despite the absence of manifest neurological symptoms. The case demonstrates the critical role of determining of creatine phosphokinase as a screening marker and the need for an integrated approach for early diagnosis. The detection of in-frame deletion creates prerequisites for the potential use of exon-skipping therapy.
- 20 May 2026
- Published by Open Systems Publications in Лечащий врач
- No. 5(29)
Progressive Duchenne/Becker muscular dystrophy, preclinical stage, deletion of exons 45-55 of the DMD gene in the hemizygous state: a clinical case from practice
Background. Duchenne/Becker progressive muscular dystrophy is an X-linked recessive disease caused by mutations in the DMD gene encoding the dystrophin protein. Deletions of exons 45-55 often correspond to the principle of preserving the reading frame, being associated with the Duchenne/Becker muscular dystrophy phenotype. Objective. To present a clinical case of the presymptomatic diagnosis of progressive Duchenne/Becker muscular dystrophy in an early-age patient with deletion of exons 45-55 of the DMD gene, analyze diagnostic markers and justify a strategy for dynamic follow-up. Materials and methods. A retrospective analysis of medical documentation with clinical, laboratory and instrumental methods was performed. In order to form a theoretical base, data was searched and systematized from scientific electronic libraries (CyberLeninka, eLibrary, PubMed, Google Academy) on progressive Duchenne/Becker muscular dystrophy (preclinical phase) and deletion of exons 45-55 of the DMD gene. The review includes literature reviews, scientific publications, and the results of clinical trials on the topic. Conclusion. A clinical case of diagnosis of progressive Duchenne/Becker muscular dystrophy in a 1-year-old male patient with isolated hyperfermentemia (ALT – 120 U/l, AST – 107.1 U/L) and a significant increase in creatine phosphokinase (4817.1 U/L) is described. Conducted: biochemical examination (creatine phosphokinase, lactate dehydrogenase, creatine phosphokinase-MV), instrumental diagnostics, including electrocardiography, ultrasound examination of the heart and abdominal cavity), molecular genetic analysis. The molecular genetic analysis method verified the hemizygous deletion of exons 45-55 of the DMD gene. The diagnosis of progressive Duchenne/Becker muscular dystrophy was established at the preclinical stage, despite the absence of manifest neurological symptoms. The case demonstrates the critical role of determining of creatine phosphokinase as a screening marker and the need for an integrated approach for early diagnosis. The detection of in-frame deletion creates prerequisites for the potential use of exon-skipping therapy.
- Open Access
- 26 March 2026
- Published by Rostov State Medical University in Medical Herald of the South of Russia
- Vol. 17 (1) , 27-31
Diagnostic aspects of autoimmune polyglandular syndrome type 1 in children: a clinical case
Objective : to highlight the difficulties of diagnosing autoimmune polyglandular syndrome type 1 (APC-1) in children, using the example of a clinical case with atypical onset. Materials and methods : the article presents a clinical case of a 3-yearold girl in whom the manifestation of APC-1 began with autoimmune hepatitis type 2, followed by the development of a classic triad of symptoms. The analysis of clinical and laboratory data and the results of a molecular genetic study was carried out. Results: molecular genetic analysis confirmed the diagnosis of APC-1 (homozygous mutation c.769C>T p.R257X in the AIRE gene). Against the background of immunosuppressive and hormone replacement therapy, positive dynamics from hepatitis was noted, however, the syndrome progressed with the addition of hypoparathyroidism and primary adrenal insufficiency, which required repeated correction of treatment. Conclusion : the described case illustrates the polymorphism of the clinical picture of APC-1 and highlights the need for caution regarding this syndrome in children with isolated autoimmune diseases. Early genetic verification is key for the timely initiation of complex therapy.
- 26 March 2026
- Published by Rostov State Medical University in Medical Herald of the South of Russia
- Vol. 17 (1) , 27-31
Open AccessDiagnostic aspects of autoimmune polyglandular syndrome type 1 in children: a clinical case
Objective : to highlight the difficulties of diagnosing autoimmune polyglandular syndrome type 1 (APC-1) in children, using the example of a clinical case with atypical onset. Materials and methods : the article presents a clinical case of a 3-yearold girl in whom the manifestation of APC-1 began with autoimmune hepatitis type 2, followed by the development of a classic triad of symptoms. The analysis of clinical and laboratory data and the results of a molecular genetic study was carried out. Results: molecular genetic analysis confirmed the diagnosis of APC-1 (homozygous mutation c.769C>T p.R257X in the AIRE gene). Against the background of immunosuppressive and hormone replacement therapy, positive dynamics from hepatitis was noted, however, the syndrome progressed with the addition of hypoparathyroidism and primary adrenal insufficiency, which required repeated correction of treatment. Conclusion : the described case illustrates the polymorphism of the clinical picture of APC-1 and highlights the need for caution regarding this syndrome in children with isolated autoimmune diseases. Early genetic verification is key for the timely initiation of complex therapy.
- 19 April 2024
- Published by Open Systems Publications in Лечащий врач
- No. 4(27)
Clinical case of hereditary thrombocytopenia in a 6 year old child with primary combined immunodeficiency condition
Background. One of the leading causes of childhood disability and mortality at the present stage is hereditary and congenital pathology. It is the problem of early diagnosis of these diseases in children that still has great scientific and practical significance. Approaches to the diagnosis of hereditary and congenital diseases are constantly being improved, and the areas of medical practice of their application are expanding. This is possible thanks to the widespread introduction of molecular genetics – a large and diverse group of molecular genetic methods designed to identify polymorphisms in gene structure. The significance of this diagnostic spectrum for medicine in general, including pediatric practice, is obvious: early detection of the disease and initiation of therapy based on the principles of evidence-based medicine, the use of drugs that are considered safe and effective based on molecular diagnostics; monitoring treatment and determining prognosis. Results. The article presents a clinical case of hereditary thrombocytopenia in a 6-year-old child with a primary immunodeficiency state. A child from the fifth pathological pregnancy, third surgical birth. The patient has had thrombocytopenia since birth. From two months of life to one year, frequent acute respiratory infections are observed (up to two times a month), from one year of age, recurrent nosebleeds are observed once or twice a month. For the first time, the diagnosis of hereditary thrombocytopenia was suspected at the Children's Regional Clinical Hospital in Belgorod. The patient was sent for further examination, in order to verify the diagnosis, at the end of 2021 to the Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology. Based on the results of a molecular genetic examination, mutations in the ETV6 genes (participated in hematopoiesis by affecting cell proliferation and differentiation) and PTEN (tumor growth suppressor) in the heterozygous state were identified. He was repeatedly hospitalized in the children's regional clinical hospital at his place of residence with the main clinical diagnosis: Primary combined immunodeficiency. Hereditary thrombocytopenia associated with a mutation of the ETV6 gene. To this day, the manifestations of hemorrhagic syndrome and thrombocytopenia in the child persist. The described case is of interest due to the rarity of this pathology, the difficulties associated with its diagnosis, and emphasizes the need for interaction between a team of specialists to achieve the most favorable prognosis for patients suffering from hereditary diseases.
- 19 April 2024
- Published by Open Systems Publications in Лечащий врач
- No. 4(27)
Clinical case of hereditary thrombocytopenia in a 6 year old child with primary combined immunodeficiency condition
Background. One of the leading causes of childhood disability and mortality at the present stage is hereditary and congenital pathology. It is the problem of early diagnosis of these diseases in children that still has great scientific and practical significance. Approaches to the diagnosis of hereditary and congenital diseases are constantly being improved, and the areas of medical practice of their application are expanding. This is possible thanks to the widespread introduction of molecular genetics – a large and diverse group of molecular genetic methods designed to identify polymorphisms in gene structure. The significance of this diagnostic spectrum for medicine in general, including pediatric practice, is obvious: early detection of the disease and initiation of therapy based on the principles of evidence-based medicine, the use of drugs that are considered safe and effective based on molecular diagnostics; monitoring treatment and determining prognosis. Results. The article presents a clinical case of hereditary thrombocytopenia in a 6-year-old child with a primary immunodeficiency state. A child from the fifth pathological pregnancy, third surgical birth. The patient has had thrombocytopenia since birth. From two months of life to one year, frequent acute respiratory infections are observed (up to two times a month), from one year of age, recurrent nosebleeds are observed once or twice a month. For the first time, the diagnosis of hereditary thrombocytopenia was suspected at the Children's Regional Clinical Hospital in Belgorod. The patient was sent for further examination, in order to verify the diagnosis, at the end of 2021 to the Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology. Based on the results of a molecular genetic examination, mutations in the ETV6 genes (participated in hematopoiesis by affecting cell proliferation and differentiation) and PTEN (tumor growth suppressor) in the heterozygous state were identified. He was repeatedly hospitalized in the children's regional clinical hospital at his place of residence with the main clinical diagnosis: Primary combined immunodeficiency. Hereditary thrombocytopenia associated with a mutation of the ETV6 gene. To this day, the manifestations of hemorrhagic syndrome and thrombocytopenia in the child persist. The described case is of interest due to the rarity of this pathology, the difficulties associated with its diagnosis, and emphasizes the need for interaction between a team of specialists to achieve the most favorable prognosis for patients suffering from hereditary diseases.
- 17 February 2023
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 102 (1)
CLINICAL CASE OF COVID-19 IN A CHILD WITH A RARE SMITH–LEMLI–OPITZ SYNDROME
Severe forms of COVID-19 are more likely to develop in children of the first year of life with genetic disorders and congenital malformations. Only a few lethal outcomes of the disease in children have been registered ongoing Worldwide over the entire period of the COVID-19 pandemic. This Article represents a clinical case of COVID-19 in a child with a rare Smith-Lemli-Opitz syndrome. On the 2nd day after the reported contact with a family member with COVID-19 the patient aged 3 years and 2 months old was hospitalized in the infectious diseases department with the diagnoses of “Severe coronavirus infection (PCR-confirmed); cardiopulmonary insufficiency; and congenital heart disease.” Since the age of 1.5 months old the patient repeatedly underwent inpatient examination and treatment with the Psycho-Neurological Department of the Belgorod Oblast Regional Children's Clinical Hospital (located in Belgorod, Russia). Furthermore, at the age of 1.5 y/o, according to the results of the medical genetic counseling, the diagnosis of Smith-Lemli-Opitz syndrome was established. Due to the COVID-19, the patient's condition deteriorated rapidly, and on the 5th day after the hospitalization the patient has died due to acute heart failure, cardiogenic pulmonary edema and pulmonary hemorrhage.
- 17 February 2023
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 102 (1)
CLINICAL CASE OF COVID-19 IN A CHILD WITH A RARE SMITH–LEMLI–OPITZ SYNDROME
Severe forms of COVID-19 are more likely to develop in children of the first year of life with genetic disorders and congenital malformations. Only a few lethal outcomes of the disease in children have been registered ongoing Worldwide over the entire period of the COVID-19 pandemic. This Article represents a clinical case of COVID-19 in a child with a rare Smith-Lemli-Opitz syndrome. On the 2nd day after the reported contact with a family member with COVID-19 the patient aged 3 years and 2 months old was hospitalized in the infectious diseases department with the diagnoses of “Severe coronavirus infection (PCR-confirmed); cardiopulmonary insufficiency; and congenital heart disease.” Since the age of 1.5 months old the patient repeatedly underwent inpatient examination and treatment with the Psycho-Neurological Department of the Belgorod Oblast Regional Children's Clinical Hospital (located in Belgorod, Russia). Furthermore, at the age of 1.5 y/o, according to the results of the medical genetic counseling, the diagnosis of Smith-Lemli-Opitz syndrome was established. Due to the COVID-19, the patient's condition deteriorated rapidly, and on the 5th day after the hospitalization the patient has died due to acute heart failure, cardiogenic pulmonary edema and pulmonary hemorrhage.
- Open Access
- 15 March 2022
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 25 (1)
The main risk factors for the development of cerebral palsy in children
Introduction. Currently, worldwide the formation of cerebral palsy (CP) makes a great contribution to the gain in childhood disability prevalence. The goal is to conduct a comparative analysis of risk factors and the main causes of the development of CP in children living in the Belgorod region for the period from 2020 to 2021. Materials and methods. There were analyzed histories of two hundred two CP children aged from four months to seven years. Results. Spastic forms of the disease predominated in the structure of infantile CP. Significantly more often this pathology occurred in premature babies at an early age and children residing in urban areas. The most frequent risk factors for the onset of the disease were such pathology of pregnancy as chronic fetoplacental insufficiency and chronic intrauterine fetal hypoxia. Delayed psycho-speech development had a leading place among all manifestations of the central nervous system in CP patients is beyond doubt. An analysis of the causes leading to the onset of the disease showed that in most cases it is not possible to discriminate one of them, since a combination of several unfavourable factors is often noted during pregnancy and parturition. CP children require constant care from relatives, long courses of complex drug and rehabilitation treatment.
- 15 March 2022
- Published by National Medical Research Center for Childrens Health in Russian Pediatric Journal
- Vol. 25 (1)
Open AccessThe main risk factors for the development of cerebral palsy in children
Introduction. Currently, worldwide the formation of cerebral palsy (CP) makes a great contribution to the gain in childhood disability prevalence. The goal is to conduct a comparative analysis of risk factors and the main causes of the development of CP in children living in the Belgorod region for the period from 2020 to 2021. Materials and methods. There were analyzed histories of two hundred two CP children aged from four months to seven years. Results. Spastic forms of the disease predominated in the structure of infantile CP. Significantly more often this pathology occurred in premature babies at an early age and children residing in urban areas. The most frequent risk factors for the onset of the disease were such pathology of pregnancy as chronic fetoplacental insufficiency and chronic intrauterine fetal hypoxia. Delayed psycho-speech development had a leading place among all manifestations of the central nervous system in CP patients is beyond doubt. An analysis of the causes leading to the onset of the disease showed that in most cases it is not possible to discriminate one of them, since a combination of several unfavourable factors is often noted during pregnancy and parturition. CP children require constant care from relatives, long courses of complex drug and rehabilitation treatment.